KUALA LUMPUR, Oct 26 (Bernama) -- George Clinical, in close collaboration with The George Institute for Global Health, recently recruited over 5,000 patients in its first-ever, groundbreaking Global Kidney Patient Trials Network (GKPTN) to accelerate kidney disease treatments.
George Clinical is a global clinical research organisation founded in the Asia-Pacific.
The concept for the GKPTN is a logical extension of its scientific and clinical operations leadership in the kidney space.
“Our ultimate goal is to grow the GKPTN to a total of 10,000 patients by the end of 2027 and this will give us the bandwidth to support dozens of clinical trials in the kidney space.
“We are well on our way to achieving our goals as we seek to provide the infrastructure necessary to make recruitment timelines shorter and reduce the time to get needed treatments to patients,” said its chief medical officer Maria Ali in a statement today.
The GKPTN aims to accelerate the development of new treatments and provide equitable benefits for the millions of people globally who suffer from chronic kidney disease (CKD) and the many rarer kidney diseases associated with glomerular nephropathies.
In early 2020, the GKPTN enrolled its first patient with the purpose of developing a network of patients with CKD willing to participate in clinical research projects accessible via a single global chronic kidney disease platform.
The GKPTN now has more than 140 sites in nine countries globally recruiting patients, including Australia, China, Japan, USA, Canada, Argentina, Brazil, Spain, and Italy with the full intention of continuing to expand the number of countries in the coming years.
The development of the GKPTN was made possible through a generous grant from AstraZeneca and serves as a clear example of a true research partnership.
-- BERNAMA
No comments:
Post a Comment